Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granite Holdings
Basel, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
GRT-001 is in Phase 1a trials in healthy volunteers, showing promising depletion of pro-inflammatory monocytes, with entry into Phase 1b in inflammatory bowel disease expected in 2025. GRT-002 is preclinical, targeting interleukin-3 for autoimmune and allergic indications, aiming to enter the clinic in 2026.[2][3][12]
- Therapeutic areas
- GastroenterologyDermatologyImmunologyRare Diseases
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Versant Venture’s Ridgeline Discovery Engine
Beyond the preview
Go deeper on Granite Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granite Holdings.